LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Akciju saraksts・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

638.17 -0.53

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

633.36

Max

642.52

Galvenie mērījumi
By Trading Economics
Ienākumi	-117M 727M
Pārdošana	-279M 3.6B
P/E Sektora vidējais	15.384 49.701
EPS	9.47
Dividenžu ienesīgums	0.51
Peļņas marža	20.17
Darbinieki	15,343
EBITDA	-234M 967M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+29.13% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	0.51% 2.39%
Nākamie ieņēmumi	2026. g. 31. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-12B 66B
Iepriekšējā atvēršanas cena	638.7
Iepriekšējā slēgšanas cena	638.17

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bearish Evidence

542.44 / 599.76 Atbalsts un pretestība

Regeneron Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 1. aug. 11:33 UTC

Peļņas

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

2026. g. 29. apr. 12:01 UTC

Peļņas

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

2026. g. 23. apr. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026. g. 11. marts 11:02 UTC

Tirgus saruna

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

2025. g. 14. dec. 08:30 UTC

Iegādes, apvienošanās, pārņemšana

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

2025. g. 1. aug. 13:16 UTC

Peļņas

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

2025. g. 1. aug. 12:40 UTC

Peļņas

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

2025. g. 1. aug. 10:41 UTC

Peļņas

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

2025. g. 1. aug. 10:41 UTC

Peļņas

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

2025. g. 1. aug. 10:40 UTC

Peļņas

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

2025. g. 1. aug. 10:38 UTC

Peļņas

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

2025. g. 1. aug. 10:37 UTC

Peļņas

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

2025. g. 1. aug. 10:35 UTC

Peļņas

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

2025. g. 1. aug. 10:34 UTC

Peļņas

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

2025. g. 1. aug. 10:33 UTC

Peļņas

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

2025. g. 1. aug. 10:32 UTC

Peļņas

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

2025. g. 1. aug. 10:31 UTC

Peļņas

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

2025. g. 1. aug. 10:31 UTC

Peļņas

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

2025. g. 1. aug. 10:30 UTC

Peļņas

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

2025. g. 1. aug. 10:30 UTC

Peļņas

Regeneron Pharma 2Q Rev $3.68B >REGN

2025. g. 1. aug. 10:30 UTC

Peļņas

Regeneron Pharma 2Q EPS $12.81 >REGN

2025. g. 1. aug. 10:30 UTC

Peļņas

Regeneron Pharma 2Q Net $1.39B >REGN

2025. g. 13. jūn. 21:42 UTC

Iegādes, apvienošanās, pārņemšana

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

2025. g. 13. jūn. 20:45 UTC

Iegādes, apvienošanās, pārņemšana

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

2025. g. 13. jūn. 20:34 UTC

Iegādes, apvienošanās, pārņemšana

Anne Wojcicki Wins Bidding for 23andMe -- Update

2025. g. 13. jūn. 20:14 UTC

Iegādes, apvienošanās, pārņemšana

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

2025. g. 13. jūn. 20:14 UTC

Iegādes, apvienošanās, pārņemšana

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

2025. g. 13. jūn. 20:14 UTC

Iegādes, apvienošanās, pārņemšana

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

2025. g. 5. jūn. 01:41 UTC

Iegādes, apvienošanās, pārņemšana

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

2025. g. 30. maijs 08:58 UTC

Karstas akcijas

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

Salīdzinājums

Cenas izmaiņa

Regeneron Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

29.13% augšup

Prognoze 12 mēnešiem

Vidējais 829.77 USD 29.13%

Augstākais 995 USD

Zemākais 641 USD

Pamatojoties uz 22 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Regeneron Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

22 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 22 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Regeneron Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

542.44 / 599.76Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.